NERV - Minerva Year-over-year net earnings per share growth for the last 12 months
Minerva Neurosciences management is depleting reserves due to the prolonged approval process for its schizophrenia drug. On GURU.Markets, this quarterly EPS chart demonstrates the results of this strategy, where the value remains at 49.10. The company relies on external CDMO contractors for production, while implementing eco-standards and electronic document management in its laboratories to control biomaterials.
Comprehensive metric breakdowns and analytics for Minerva (NERV)
- market value and analyst target forecast:
- market capitalization statistics:
- book capitalization indicators:
- debt burden and liquidity indicators:
Debt to Equity Minerva Neurosciences|NERV - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Minerva Neurosciences|NERV - Company Cumulative Debt|Debt to Book Value Minerva Neurosciences Corp|NERV - Company Long-Term Debts|Company Short-Term Debt Minerva Neurosciences|Quick Liquidity minervaneurosciences.com
- earnings and valuation multiples indicators:
NERV - Company Net Income|Expected Profit Minerva Neurosciences|NERV - Business Payback Period|Forward P/E Multiple Minerva Neurosciences Corp|NERV - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Minerva Neurosciences Corp|NERV - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Minerva Neurosciences|NERV - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months minervaneurosciences.com|NERV - Earnings per share growth this year|Earnings growth forecast for next year Minerva Neurosciences
Comprehensive company analysis:Minerva Neurosciences, Inc., NERV
This indicator captures the percentage deviation of current quarter earnings per share relative to the same period last year, allowing for an assessment of corporate development dynamics. By analyzing the quarterly change in earnings per share, a Minerva Neurosciences (NERV) investor will see that in the absence of revenue, the metric reflects only the capital burn rate prior to the delivery of clinical trial results.
Competitor analysis
Biogen (BIIB) - Year-over-year earnings per share growth for the last twelve months|Neurocrine - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months RGC|Year-over-year earnings per share growth for the last twelve months AXSM|Quarterly EPS earnings growth ACAD|Quarterly EPS earnings growth xenon-pharma.com (XENE)|Viking Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months SUPN|CPRX - Year-over-year earnings per share growth for the last twelve months|DNLI (Denali Corp) - Year-over-year earnings per share growth for the last 12 months|HRMY: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months biohavenpharma.com (BHVN)|Year-over-year net earnings per share growth for the last 12 months AMLX|Quarterly EPS earnings growth Trevi Therapeutics Inc|Year-over-year earnings per share growth for the last twelve months Praxis Medicines (PRAX)|AVXL (Anavex Life Sciences Corp) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months CeriBell, Inc. CBLL|prothena.com (PRTA) - Earnings per share growth in annualized terms for the last twelve months|ALEC - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Annexon Biosciences ANNX|OMER: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Neurogene Therapeutics|ACIU (AC Immune) - Quarterly EPS earnings growth|voyagertherapeutics.com (VYGR) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth NMRA|SCLX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Tevogen Bio Holdings, Inc. TVGN|ACOG: Year-over-year earnings per share growth for the last 12 months|Cognition Therapeutics, Inc. - Quarterly EPS earnings growth|inhibikase.com (IKT) - Year-over-year net earnings per share growth for the last 12 months|SAVA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Assertio (ASRT)|Year-over-year earnings per share growth for the last twelve months Coya Therapeutics Inc|VistaGen Therapeutics Inc (VTGN) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Ovid Therapeutics Inc. (OVID)|acumenpharm.com - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth CRVO (CervoMed)|Alterity Therapeutics Ltd. (ATHE) - Earnings per share growth in annualized terms for the last twelve months|CLNN - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months PEPG (PepGen Inc.)|JUNS (Jupiter Neurosciences) - Year-over-year net earnings per share growth for the last 12 months|RLMD (relmada.com) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last twelve months Annovis Bio|Year-over-year earnings per share growth for the last 12 months GRCE (Grace Tx)|Quarterly EPS earnings growth AIFF|KLTO - Earnings per share growth in annualized terms for the last twelve months|NeuroSense Therapeutics Ltd. - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth revivapharma.com RVPH|MTVA - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months NRXS (NeurAxis Inc.)|heliusmedical.com (HSDT) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Passage Bio (PASG)|Year-over-year earnings per share growth for the last twelve months Neuphoria Therapeutics, Inc.|Year-over-year net earnings per share growth for the last 12 months athira.com (ATHA)|Quarterly EPS earnings growth ADXN|Year-over-year net earnings per share change for the last twelve months alzamend.com|Year-over-year earnings per share growth for the last twelve months Cyclerion Therapeutics, Inc. CYCN|PTIX: Year-over-year earnings per share growth for the last 12 months|Pasithea - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Cortigent, Inc.|Avenue Therapeutics, Inc. (ATXI) - Year-over-year earnings per share growth for the last twelve months|Brainstorm Cell Therapeutics Inc. - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months CARA|Year-over-year earnings per share growth for the last twelve months CHRO|Quarterly EPS earnings growth ELYM|Quarterly EPS earnings growth intracellulartherapies.com (ITCI)|Longboard Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months MRNS|NKGN - Year-over-year earnings per share growth for the last twelve months|NRBO (NeuroBo Pharma) - Year-over-year earnings per share growth for the last 12 months|SAGE: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months synaptogen.com (SNPX)|Year-over-year net earnings per share growth for the last 12 months TRVN|Quarterly EPS earnings growth Vigil Neuro|Year-over-year earnings per share growth for the last twelve months Anew Medical, Inc. (WENA)|CERE (Cerevel Corp) - Year-over-year earnings per one share growth for the last 12 months
